An innovative medical trial has found that administering stem cells to unborn babies diagnosed with spina bifida as part of a surgical repair can be a "significant breakthrough" in treating birth defects.
Trial Details and Safety
The US-based trial examined six developing infants with the 'open' form of spina bifida. Medical teams placed regenerative cells sourced from the maternal placenta on the exposed area of the developing neural column as part of the surgical correction.
Importantly, the cell therapy proved to be secure. Researchers confirmed that the treatment did not lead to neoplasms, hinder surgical recovery, or block the correction of co-occurring hindbrain herniation.
Promising Outcomes
Post-birth MRI scans showed a successful correction of brainstem displacement in every participant. This brain structure normalization is a key indicator for improved motor skills and quality of life.
"In the event it allows additional babies able to walk who otherwise would not, it may emerge as the new treatment paradigm," noted the study director. "These findings are profoundly encouraging and open the door to numerous possible novel therapies."
Future Implications and Hope
Commentators reviewing the findings have suggested that additional validation of these apparent benefits could herald a "new era" in fetal surgery. The possibility of ameliorating neural deficits occurring during fetal development is viewed as a paradigm-shifting aim.
Notably important would be improvements in bladder and bowel function, which are typical difficulties for those diagnosed with this condition.
The Path Forward
While this initial trial involved a limited number of patients, its safety demonstration and positive signals create a solid basis for larger, more comprehensive studies. The addition of cellular treatment with proven prenatal surgical methods holds considerable promise for transforming outcomes for future generations with myelomeningocele.